Evidence map›Paper›PMID 39896937›Full record

ArticleDrug design, development and therapy2025

Pharmacodynamic Modeling of Warfarin Dosing Algorithm for Cardiovascular Patients in Indonesia: A Tailored Method to Anticoagulation Therapy.

Norisca Aliza Putriana, Irma Rahayu Latarissa, Taofik Rusdiana, Tina Rostinawati, Mohammad Rizki Akbar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Effect of Spinach (Journal of blood medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Norisca Aliza PutrianaDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Irma Rahayu LatarissaDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0009-0009-6535-6685
Taofik RusdianaDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0002-3321-2179
Tina RostinawatiDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0002-7139-8250
Mohammad Rizki AkbarDepartment of Cardiovascular, Faculty of Medicine, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0001-9662-8676

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Warfarin is an anticoagulant drug widely used for treating thromboembolism-related conditions. The main challenge with this drug is the high variability in patients response, which is influenced by both clinical, non-clinical, and genetic factors, such as Patients and Methods: A total of 77 research subjects were selected using consecutive sampling based on the inclusion criteria of cardiac outpatients on warfarin for ≥3 months with PT-INR data, complete medical records, and willingness to participate. Exclusion criteria included vitamin K use and inability to follow up. Patients demographic data and clinical characteristics were collected from medical records. Blood samples were obtained for genetic testing of Results: Statistical analysis using the Kruskal-Wallis test showed that the CC, CT, and TT genotypes were significantly associated with warfarin dose (p = 0.02). Furthermore, the Mann-Whitney test results showed that gender did not have a significant relationship with warfarin dose (p = 0.16). The Spearman Rank correlation test showed that age (p = 0.02) and BMI (p = 0.03) had significant relationships with warfarin dose (p < 0.05). However, gender (p = 0.89) had no effect, while age (p = 0.01), BMI (p = 0.01), and genotype (p = 0.01) significantly influenced warfarin dose determination. Conclusion: In conclusion, the combined contribution of age (8.76%), BMI (7.95%), and

Indexed as

AnticoagulantsCytochrome P450 Family 4Pharmacogenomic VariantsWarfarinAdultAgedAged, 80 and overAlgorithmsCytochrome P-450 CYP2C9FemaleHumansMaleMiddle AgedVitamin K Epoxide ReductasesAnticoagulantsCYP2C9 protein, humanCYP4F2 protein, humanCytochrome P-450 CYP2C9Cytochrome P450 Family 4Vitamin K Epoxide ReductasesVKORC1 protein, humanWarfarinanticoagulation therapycardiovascular diseaseCYP4F2 genotypegenetic polymorphismwarfarin dosing

Identifiers

PMID39896937
PMCPMC11787782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.